Format

Send to

Choose Destination
Prostate. 2007 May 1;67(6):614-22.

Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.

Author information

1
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.

Abstract

BACKGROUND:

Caveolin-1 protein suppresses apoptotic cell death in prostate cancer. The objectives of this study were to investigate the association of Caveolin-1 expression with established features of prostate cancer as well as overall and aggressive disease recurrence in patients treated with radical prostatectomy (RP).

METHODS:

Caveolin-1 immunostaining was performed on a tissue microarray containing prostatectomy specimen cores from 232 consecutive patients treated with RP for clinically localized prostatic adenocarcinoma. Caveolin-1 over-expression was defined as more than 50% of cells staining positively for Caveolin-1. Patients were categorized as having features of aggressive disease recurrence if they had a positive metastatic work-up, post-recurrence PSA doubling time less than 10 months, and/or failure to respond to local salvage radiation therapy.

RESULTS:

Seventy patients (30.2%) exhibited over-expression of Caveolin-1. Caveolin-1 over-expression was associated with higher pathologic Gleason sum (P=0.038) and higher pre-operative PSA level (P=0.024). Patients with Caveolin-1 over-expression were at increased risk of PSA recurrence after surgery (P=0.023) in univariate but not in standard post-operative multivariate analysis. However, patients with Caveolin-1 over-expression were at increased risk of aggressive prostate cancer recurrence in both univariate and multivariate analysis (P<0.001 and P=0.001, respectively).

CONCLUSIONS:

Over-expression of Caveolin-1 was associated with established features of prostate cancer and aggressive PSA recurrence. Caveolin-1 might help identify patients at high risk of developing aggressive prostate cancer recurrence, thus allowing selection of patients who might benefit from early systemic therapeutic intervention.

PMID:
17299799
DOI:
10.1002/pros.20557
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center